POSTER_MBA, CLIA, EIA Borrelia_Comparison of methods for determining Borrelia antibodies.pdf (pdf - 2117 kB) POSTER_MBA multiplex diagnostics of antinuclear antibodies in microtiter plate format (Czech republic).pdf (pdf - 450 kB) POSTER_MBA ANA_A comparative study of MBA with conventional routine methods for the detection of antibodies associated with SLE and Scl in Czech population (Czech Republic, 2024).pdf (pdf - 673 kB) POSTER_MBA ANA_Assessment of the possible role of Micro-Array testing in the diagnostics flow-chart of a specialist referral laboratory for autoimmune diseases (Italy, 2024).pdf (pdf - 291 kB) POSTER_MBA ANA_ICAP classification patterns under magnifying glass of multiplex antibodies detections (Romania,2024).pdf (pdf - 545 kB) POSTER_Immunological imprinting by seasonal coronaviruses and previous herpesvirus infections in long covid patients (Netherlands, 2024).pdf (pdf - 2673 kB) POSTER_Enhanced detection of antinuclear antiodies in IIM - A comparative study of MBA and conventional methods.pdf (pdf - 219 kB) POSTER_MBA Borrelia_Microarray immunoblot in the diagnosis of pediatric Lyme neuroborreliosis (Czech Rebublic).pdf (pdf - 2022 kB) POSTER_MBA Borrelia_(Hungarian).pdf (pdf - 1397 kB) SARS-CoV-2 in tumor tissue in glioblastoma patients (Poland, 2025).pdf Prevalence of Borrelia burgdorferi sensu lato infection in the Czech Republic.pdf Granulocytic Anaplasmosis -underdiagnosed disease in veterinary and human medicine in Romania (Romania, 2025).pdf Correlation between COVID-19 severity and previous exposure of patients to Borrelia spp. (Poland, 2022).pdf Antibodies to NCP, RBD and S2 SARS-CoV-2 in Vaccinated and Unvaccinated HealthcareWorkers (Poland, 2022).pdf Clinical outcomes, immunogenicity, and safety of BNT162b22 Vaccine in Primary Antibody Deficiency (Czech Republic, 2022).pdf COVID-19 in a patient with neuroendocrine pancreatic cancer - Case report (Poland, 2022).pdf Dynamics of anti-SARS-CoV-2 seroconversion in individual patients at the population level (Poland, 2022).pdf Hidden fraction of Polish population immumne to SARS-CoV-2 in May 2021 (Poland, 2022).pdf Immune response to COVID-19 mRNA Vaccine - A Pilot Study (Poland, 2021).pdf Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF patients (Czech Republic, 2021).pdf Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients (Czech Republic, 2021).pdf Impaired Humoral Response to Third Dose of BNT162b2 mRNA COVID-19 Vaccine Despite Detectable Spike Protein-specific T cells in Lung Transplant Recipients (Czech Republic, 2021).pdf Dynamics and correlation with commercial serologic tests (Belgium, 2021).pdf Relationship between Humoral Response in COVID-19 and Seasonal Influenza Vaccination (Poland, 2022).pdf SARS-CoV-2 spike glycoprotein-reactive T cells can be readily expanded from COVID-19 vaccinated donors (Czech Republic, 2021).pdf A systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients (USA, 2022).pdf Antibody Tests May Be Widely Accepted (China, 2022).pdf Humoral Response after SARS-CoV-2 Vaccination in Prostate Cancer Patients (Poland, 2023).pdf IgG autoantibodies against ACE2 in SARS-CoV-2 infected patients (Poland, 2022).pdf Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Diseas (Czech Republic, 2023).pdf SARS antibody NCP, RBD and S2 in women vaccinated with booster Pfizer Vaccine and infected in meantime with SARS-CoV-2 (Poland, 2022).pdf (pdf - 376 kB) SARS-CoV-2 specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressive patients (Czech Republic, 2022).pdf SARS-CoV-2 Viral Load Assessment in Lung Transplantation (Czech Republic, 2021).pdf Influenza vaccination as a prognostic factor of humoral IgA responses to SARS-CoV-2 infection (MBA_2024, Poland).pdf Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant (Poland, 2022).pdf Association between the Seroprevalence of Antibodies against Seasonal coronaviruses and SARS-CoV-2 (Poland, 2023).pdf SARS Antibodies NCP, RBD and S2 in Women Vaccinated with Booster Pfizer Vaccine and infected in meantime with SARS-CoV-2 (Poland, 2022).pdf Humoral_response_after_breakthrough_SARS-CoV-2_inf.pdf Humoral anti-SARS-CoV-2 response in patients with different long COVID phenotypes (Poland, 2024).pdf Dynamics of the level of anit-SARS antibodies within a year after three vaccinations of patients with prostate cancer (Poland, 2025).pdf Dynamics of the level of anit-SARS antibodies within a year after three vaccinations of patients with prostate cancer (Poland, 2025).pdf Can the Epstein–Barr Virus Play a Role in the Development of Prostate Cancer? (Poland, 2024).pdf Serum Anti-Zta and Anti-LMP1 Antibodies in Oropharyngeal Cancer Related to Epstein–Barr Virus—Diagnostic Usefulness (Poland, 2024).pdf Could MMP3 and MMP9 serve as biomarkers in EBV-related oropharyngeal cancer (MBA_2024, Poland).pdf Serum TLR2 and TLR9 in Prostate Cancer Patients in Relation to EBV Status (Poland, 2024).pdf JC Polyoma virus in prostate cancer - friend or Foe (Poland, 2025).pdf The impact of type 2 diabetes on selected clinical parameters and serological markers in patients with EBV-related oropharyngeal cancer (Poland, 2025).pdf The impact of type 2 diabetes on selected clinical parameters and serological markers in patients with EBV-related oropharyngeal cancer (Poland, 2025).pdf TestLine publications_30.5.2025.pdf (pdf - 722 kB)